Please ensure Javascript is enabled for purposes of website accessibility

Why Corcept Therapeutics Incorporated Shares Dipped

By Sean Williams – Jan 31, 2014 at 2:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Corcept shares drop after the company reports its fourth-quarter results. Is this a buying opportunity or a reason to hit the exits?

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Corcept Therapeutics (CORT -1.88%), a biopharmaceutical company focused on developing therapies to treat severe metabolic and psychiatric disorders, dropped as much as 14% after announcing its fourth-quarter-earnings results.

So what: For the quarter, Corcept Therapeutics reported a 56% increase in sequential quarterly revenue to $4.1 million thanks to growing sales of its only FDA-approved drug, Korlym, an oral treatment of hyperglycemia secondary to endogenous Cushing's syndrome in adults with type 2 diabetes or who are ineligible for surgery. Although Corcept didn't provide any EPS figures in its release, it did guide toward $24 million to $28 million in Korlym sales in fiscal 2014, which is ahead of the $22.5 million Wall Street had been expecting.

Now what: Today's move lower looks like a combination of a number of factors. First, Corcept's share price has been very volatile of late, so today's reaction could be nothing more than traders taking gains following a wild couple of days of trading. It could also be based on conference-call commentary from Corcept CEO Joseph Belanoff who didn't disclose a lot of the specifics surrounding the launch of Korlym in terms of the number of patients being treated, or the number of physicians the sales staff is marketing toward. Finally, the simple fact that Korlym produced only $4.1 million this quarter and Corcept is valued at $335 million (as of this writing) could be enough to scare short-term-minded investors away. While top-line growth certainly looks as if it's about to pick up, I don't see Corcept's losses abating anytime soon – and that's more than enough to keep me firmly planted on the sidelines.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.